Upadacitinib

Upadacitinib has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. It is an approved medicine. The newest paper, Feb 10, 2026: “The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI”.

InterventionApproved 2019

1 paper studies it1 findingUpdated

See all 1 papers on upadacitinib

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 96 trials, none about aging, 4 with no results posted.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • 96 trials, none about aging, 4 with no results posted
  • 65 of 96 trials sponsored by its developers
  • Humans1

What acts on upadacitinib?

1

Studies name prac recommendations as acting on upadacitinib.

Prac recommendations

no changein humans1

1 study
  1. Prac recommendations were not clearly linked with upadacitinib in humans (rheumatoid arthritis).

    “Notably, upadacitinib utilization remained stable despite regulatory restrictions.”

    Humansrheumatoid arthritis

    The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI

    Journal of personalized medicine

More on Prac recommendations

Has upadacitinib been tested in people?

0 of 96 about aging

Yes: 1 observational study in people have been published, and 95 trials are registered.

Approved

  • FDA Rinvoq

    Aug 16, 2019Active Rheumatoid Arthritis

  • EMA Rinvoq

    Dec 16, 2019Arthritis, Rheumatoid, Arthritis, Psoriatic, Axial Spondyloarthritis, Spondylitis, Ankylosing, Giant Cell Arteritis, Dermatitis, Atopic, Colitis, Ulcerative, Crohn Disease, Alopecia Areata, Vitiligo, Non-Segmental Vitiligo, Severe Alopecia Areata, polyarticular juvenile idiopathic arthritis, Active Rheumatoid Arthritis, Moderate-to-Severe Atopic Dermatitis, non radiographic axial spondyloarthritis, moderately to severely active ulcerative colitis

  • FDA Rinvoq LQ

    Apr 26, 2024Active Rheumatoid Arthritis

Repurposing

All 21

In trials

  • Acute Severe Ulcerative Colitis

    Phase 4Recruiting2 trials

  • Ulcerative colitis acute

    Phase 4Recruiting2 trials

Stopped

  • NCT06773403TerminatedPrurigo nodularis

    There was not a big enough patient population to meet recruitment goals

Who is developing upadacitinib?

3 companies: AbbVie, Rheinische Friedrich-Wilhelms-Universitaet Bonn and Takeda.

Companies
  • AbbViePhase 4atopic dermatitis, severe alopecia areata
  • Rheinische Friedrich-Wilhelms-Universitaet BonnPhase 3giant cell arteritis
  • TakedaPhase 3Crohn's disease

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months